434
Views
60
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer

, , , , , , , , , , & show all
Pages 150-157 | Received 22 Oct 2013, Accepted 28 Jan 2014, Published online: 07 Mar 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Hadeer Ehab Barakat, Raghda R. S. Hussein, Ahmed Abdullah Elberry, Mamdouh Ahmed Zaki & Mamdouh Elsherbiny Ramadan. (2022) Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis. Expert Review of Anticancer Therapy 22:4, pages 415-436.
Read now
Richard E Kast, Nicolas Skuli, Samuel Cos, Georg Karpel-Massler, Yusuke Shiozawa, Ran Goshen & Marc-Eric Halatsch. (2017) The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy. Breast Cancer: Targets and Therapy 9, pages 495-514.
Read now
Nicoletta Provinciali, Matteo Lazzeroni, Massimiliano Cazzaniga, Franco Gorlero, Barbara K Dunn & Andrea DeCensi. (2015) Metformin: risk-benefit profile with a focus on cancer. Expert Opinion on Drug Safety 14:10, pages 1573-1585.
Read now

Articles from other publishers (57)

Zhipeng Wu, Wei Wang, Lengyun Wei & Shenglong Zhu. (2023) Current status and frontier tracking of clinical trials on Metformin for cancer treatment. Journal of Cancer Research and Clinical Oncology 149:18, pages 16931-16946.
Crossref
Simon R. Lord & Adrian L. Harris. (2023) Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?. British Journal of Cancer 128:6, pages 958-966.
Crossref
Jiahui Huang, Yiwei Tong, Jin Hong, Ou Huang, Jiayi Wu, Jianrong He, Weiguo Chen, Yafen Li, Xiaosong Chen & Kunwei Shen. (2022) Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial. Breast Cancer Research and Treatment 197:3, pages 525-533.
Crossref
Bo Peng, Si-Yuan Zhang, Ka Iong Chan, Zhang-Feng Zhong & Yi-Tao Wang. (2023) Novel Anti-Cancer Products Targeting AMPK: Natural Herbal Medicine against Breast Cancer. Molecules 28:2, pages 740.
Crossref
Kathy Han, Anthony Fyles, Tina Shek, Jennifer Croke, Neesha Dhani, David D'Souza, Ting-Yim Lee, Naz Chaudary, Jeffrey Bruce, Melania Pintilie, Rob Cairns, Douglass Vines, Sara Pakbaz, David Jaffray, Ur Metser, Marjan Rouzbahman, Michael Milosevic & Marianne Koritzinsky. (2022) A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer. Clinical Cancer Research 28:24, pages 5263-5271.
Crossref
Pamela J. Goodwin, Bingshu E. Chen, Karen A. Gelmon, Timothy J. Whelan, Marguerite Ennis, Julie Lemieux, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Hobday, Judith M. Bliss, Priya Rastogi, Manuela Rabaglio-Poretti, Som D. Mukherjee, John R. Mackey, Vandana G. Abramson, Conrad Oja, Robert Wesolowski, Alastair M. Thompson, Daniel W. Rea, Paul M. Stos, Lois E. Shepherd, Vuk Stambolic & Wendy R. Parulekar. (2022) Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer. JAMA 327:20, pages 1963.
Crossref
Ngozi D. Akingbesote, Aaron Norman, Wanling Zhu, Alexandra A. Halberstam, Xinyi Zhang, Julia Foldi, Maryam B. Lustberg & Rachel J. Perry. (2022) A precision medicine approach to metabolic therapy for breast cancer in mice. Communications Biology 5:1.
Crossref
Hadeer Ehab Barakat, Raghda R. S. Hussein, Ahmed Abdullah Elberry, Mamdouh Ahmed Zaki & Mamdouh Elsherbiny Ramadan. (2022) The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial. Scientific Reports 12:1.
Crossref
Hongyun Zhao, Kenneth D. Swanson & Bin Zheng. (2021) Therapeutic Repurposing of Biguanides in Cancer. Trends in Cancer 7:8, pages 714-730.
Crossref
Pamela J. Goodwin, Ryan J. O. Dowling, Marguerite Ennis, Bingshu E. Chen, Wendy R. Parulekar, Lois E. Shepherd, Margot J. Burnell, Rachel Vander Meer, Andrea Molckovsky, Anagha Gurjal, Karen A. Gelmon, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Whelan, Timothy J. Hobday, Priya Rastogi, Manuela Rabaglio-Poretti, Julie Lemieux, Alastair M. Thompson, Daniel W. Rea & Vuk Stambolic. (2021) Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. npj Breast Cancer 7:1.
Crossref
Tahereh Farkhondeh, Alireza Amirabadizadeh, Hamed Aramjoo, Silvia Llorens, Babak Roshanravan, Farhad Saeedi, Marjan Talebi, Mehdi Shakibaei & Saeed Samarghandian. (2021) Impact of Metformin on Cancer Biomarkers in Non-Diabetic Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials. Current Oncology 28:2, pages 1412-1423.
Crossref
Toshiaki Iwase, Xiaoping Wang, Tushaar Vishal Shrimanker, Mikhail G. Kolonin & Naoto T. Ueno. (2021) Body composition and breast cancer risk and treatment: mechanisms and impact. Breast Cancer Research and Treatment 186:2, pages 273-283.
Crossref
Wenhui Liu, Ying Wang, Jianquan Luo, Mouze Liu & Zhiying Luo. (2021) Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors. Frontiers in Immunology 11.
Crossref
Ji Hoon Jung, Jisung Hwang, Ju-Ha Kim, Deok Yong Sim, Eunji Im, Ji Eon Park, Woon Yi Park, Bum-Sang Shim, Bonglee Kim & Sung-Hoon Kim. (2021) Phyotochemical candidates repurposing for cancer therapy and their molecular mechanisms. Seminars in Cancer Biology 68, pages 164-174.
Crossref
Veronica C. Jones, Eric C. Dietze, Tijana Jovanovic-Talisman, Jeannine S. McCune & Victoria L. Seewaldt. (2020) Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer. Frontiers in Public Health 8.
Crossref
Gad Rennert, Hedy S. Rennert, Naomi Gronich, Mila Pinchev & Stephen B. Gruber. (2020) Use of metformin and risk of breast and colorectal cancer. Diabetes Research and Clinical Practice 165, pages 108232.
Crossref
Chidiebere V. Ugwueze, Odunze J. Ogamba, Ekenechukwu E. Young, Belonwu M. Onyenekwe & Basil C. Ezeokpo. (2020) Metformin: A Possible Option in Cancer Chemotherapy. Analytical Cellular Pathology 2020, pages 1-10.
Crossref
Ronald A. Lubet, Brandy M. Heckman-Stoddard, Jennifer T. Fox, Fariba Moeinpour, M. Margaret Juliana, Robert H. Shoemaker & Clinton J. Grubbs. (2020) Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers. Cancer Prevention Research 13:3, pages 283-290.
Crossref
Francesca Aroldi & Simon R. Lord. (2019) Window of opportunity clinical trial designs to study cancer metabolism. British Journal of Cancer 122:1, pages 45-51.
Crossref
Reema S. Wahdan-Alaswad & Ann D. Thor. 2020. Metformin [Working Title]. Metformin [Working Title].
J. Rahmani, N. Manzari, J. Thompson, S. K. Gudi, M. Chhabra, G. Naik, S. M. Mousavi, H. K. Varkaneh, C. Clark & Y. Zhang. (2019) The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose–response of randomized clinical trials. Clinical and Translational Oncology 22:1, pages 37-49.
Crossref
Samson Samuel, Elizabeth Varghese, Peter Kubatka, Chris Triggle & Dietrich Büsselberg. (2019) Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer. Biomolecules 9:12, pages 846.
Crossref
Hao Cai, Ruth S. Everett & Dhiren R. Thakker. (2019) Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours. British Journal of Pharmacology 176:15, pages 2724-2735.
Crossref
Mona Shehata, Hyeyeon Kim, Ravi Vellanki, Paul D. Waterhouse, Mathepan Mahendralingam, Alison E. Casey, Marianne Koritzinsky & Rama Khokha. (2019) Identifying the murine mammary cell target of metformin exposure. Communications Biology 2:1.
Crossref
Federica Barbieri, Ivan Verduci, Valentina Carlini, Gianluigi Zona, Aldo Pagano, Michele Mazzanti & Tullio Florio. (2019) Repurposed Biguanide Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of Intracellular Chloride Channel 1 Activity. Frontiers in Oncology 9.
Crossref
Mohsin HK Roshan, Yan K Shing & Nikolai P Pace. (2019) Metformin as an adjuvant in breast cancer treatment. SAGE Open Medicine 7, pages 205031211986511.
Crossref
K. Kalinsky, J. A. Sparano, X. Zhong, E. Andreopoulou, B. Taback, L. Wiechmann, S. M. Feldman, P. Ananthakrishnan, A. Ahmad, S. Cremers, A. N. Sireci, J. R. Cross, D. K. Marks, P. Mundi, E. Connolly, K. D. Crew, M. A. Maurer, H. Hibshoosh, S. Lee & D. L. Hershman. (2018) Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial. Clinical and Translational Oncology 20:11, pages 1474-1483.
Crossref
Ales Vancura, Pengli Bu, Madhura Bhagwat, Joey Zeng & Ivana Vancurova. (2018) Metformin as an Anticancer Agent. Trends in Pharmacological Sciences 39:10, pages 867-878.
Crossref
Rita Mancini, Alessia Noto, Maria Elena Pisanu, Claudia De Vitis, Marcello Maugeri-Saccà & Gennaro Ciliberto. (2018) Metabolic features of cancer stem cells: the emerging role of lipid metabolism. Oncogene 37:18, pages 2367-2378.
Crossref
A. Talaei, A. Moradi & F. Rafiei. (2017) The evaluation of the effect of metformin on breast fibrocystic disease. Breast Disease 37:2, pages 49-53.
Crossref
Lu Chen, Jessica Chubak, Denise M. Boudreau, William E. Barlow, Noel S. Weiss & Christopher I. Li. (2017) Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis. Cancer Research 77:21, pages 6033-6041.
Crossref
Yannan Zhao, Chengcheng Gong, Zhonghua Wang, Jian Zhang, Leiping Wang, Sheng Zhang, Jun Cao, Zhonghua Tao, Ting Li, Biyun Wang & Xichun Hu. (2017) A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer. Oncotarget 8:48, pages 84224-84236.
Crossref
Brandy M. Heckman-Stoddard, Andrea DeCensi, Vikrant V. Sahasrabuddhe & Leslie G. Ford. (2017) Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia 60:9, pages 1639-1647.
Crossref
Ameet K. Mishra, Christopher R. Parish, Ma-Li Wong, Julio Licinio & Anneke C. Blackburn. (2017) Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer. PLOS ONE 12:5, pages e0178454.
Crossref
Kunal Maniar, Amal Moideen, Ankur Mittal, Amol Patil, Amitava Chakrabarti & Dibyajyoti Banerjee. (2017) A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug?. Pharmacological Research 117, pages 103-128.
Crossref
K. Kalinsky, T. Zheng, H. Hibshoosh, X. Du, P. Mundi, J. Yang, S. Refice, S. M. Feldman, B. Taback, E. Connolly, K. D. Crew, M. A. Maurer & D. L. Hershman. (2016) Proteomic modulation in breast tumors after metformin exposure: results from a “window of opportunity” trial. Clinical and Translational Oncology 19:2, pages 180-188.
Crossref
Matteo Lazzeroni & Sara Gandini. 2017. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Benjamin D. HopkinsMarcus D. GoncalvesLewis C. Cantley. (2016) Obesity and Cancer Mechanisms: Cancer Metabolism. Journal of Clinical Oncology 34:35, pages 4277-4283.
Crossref
Elizabeth M. Cespedes FelicianoCandyce H. KroenkeJeffrey A. MeyerhardtCarla M. PradoPatrick T. BradshawAndrew J. DannenbergMarilyn L. KwanJingjie XiaoCharles QuesenberryErin K. WeltzienAdrienne L. CastilloBette J. Caan. (2016) Metabolic Dysfunction, Obesity, and Survival Among Patients With Early-Stage Colorectal Cancer. Journal of Clinical Oncology 34:30, pages 3664-3671.
Crossref
Jessica K. Paulus, Christina D. Williams, Furha I. Cossor, Michael J. Kelley & Robert E. Martell. (2016) Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer. Cancer Epidemiology, Biomarkers & Prevention 25:10, pages 1418-1425.
Crossref
Marcello Maugeri-Saccà, Maddalena Barba, Patrizia Vici, Laura Pizzuti, Domenico Sergi, Teresa Catenaro, Luigi Di Lauro, Marcella Mottolese, Daniele Santini, Michele Milella & Ruggero De Maria. (2016) Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. Critical Reviews in Oncology/Hematology 106, pages 132-142.
Crossref
Jun Gong, Gauri Kelekar, James Shen, John Shen, Sukhpreet Kaur & Monica Mita. (2016) The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development. Targeted Oncology 11:4, pages 447-467.
Crossref
Hui-Hui Zhang & Xiu-Li Guo. (2016) Combinational strategies of metformin and chemotherapy in cancers. Cancer Chemotherapy and Pharmacology 78:1, pages 13-26.
Crossref
Young Kwang Chae, Ayush Arya, Mary-Kate Malecek, Daniel Sanghoon Shin, Benedito Carneiro, Sunandana Chandra, Jason Kaplan, Aparna Kalyan, Jessica K. Altman, Leonidas Platanias & Francis Giles. (2016) Repurposing metformin for cancer treatment: current clinical studies. Oncotarget 7:26, pages 40767-40780.
Crossref
Brandy M. Heckman-Stoddard, Sara Gandini, Matteo Puntoni, Barbara K. Dunn, Andrea DeCensi & Eva Szabo. (2016) Repurposing old drugs to chemoprevention: the case of metformin. Seminars in Oncology 43:1, pages 123-133.
Crossref
Sandra Schmitz, François Duhoux & Jean-Pascal Machiels. (2016) Window of opportunity studies: Do they fulfil our expectations?. Cancer Treatment Reviews 43, pages 50-57.
Crossref
Naomi Gronich & Gad Rennert. 2016. Trends in Breast Cancer Prevention. Trends in Breast Cancer Prevention 183 212 .
Laura Camacho, Atreyi Dasgupta & Sao Jiralerspong. (2015) Metformin in breast cancer - an evolving mystery. Breast Cancer Research 17:1.
Crossref
Ryan JO Dowling, Saroj Niraula, Martin C Chang, Susan J Done, Marguerite Ennis, David R McCready, Wey L Leong, Jaime M Escallon, Michael Reedijk, Pamela J Goodwin & Vuk Stambolic. (2015) Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Research 17:1.
Crossref
M. Marous, I. Bièche, X. Paoletti, M. Alt, A.R.A. Razak, A. Stathis, M. Kamal & C. Le Tourneau. (2015) Designs of preoperative biomarkers trials in oncology: a systematic review of the literature. Annals of Oncology 26:12, pages 2419-2428.
Crossref
Andrea DeCensi, Matteo Puntoni, Aliana Guerrieri-Gonzaga, Massimiliano Cazzaniga, Davide Serrano, Matteo Lazzeroni, Andrea Vingiani, Oreste Gentilini, Marilena Petrera, Giuseppe Viale, Jack Cuzick, Bernardo Bonanni & Giancarlo Pruneri. (2015) Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial . Cancer Prevention Research 8:10, pages 888-894.
Crossref
Marianne Koritzinsky. (2015) Metformin: A Novel Biological Modifier of Tumor Response to Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics 93:2, pages 454-464.
Crossref
Alessandra Silvestri, Francesco Palumbo, Ignazio Rasi, Daniela Posca, Theodora Pavlidou, Serena Paoluzi, Luisa Castagnoli & Giovanni Cesareni. (2015) Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions. PLOS ONE 10:8, pages e0136250.
Crossref
Ivana Sestak & Jack Cuzick. (2015) Update on breast cancer risk prediction and prevention. Current Opinion in Obstetrics & Gynecology 27:1, pages 92-97.
Crossref
Erina Vlashi & Frank Pajonk. (2015) The metabolic state of cancer stem cells—a valid target for cancer therapy?. Free Radical Biology and Medicine 79, pages 264-268.
Crossref
Diana Hatoum & Eileen M. McGowan. (2015) Recent Advances in the Use of Metformin: Can Treating Diabetes Prevent Breast Cancer?. BioMed Research International 2015, pages 1-13.
Crossref
Andrea DeCensi, Matteo Puntoni, Sara Gandini, Aliana Guerrieri-Gonzaga, Harriet Ann Johansson, Massimiliano Cazzaniga, Giancarlo Pruneri, Davide Serrano, Matthias Schwab, Ute Hofmann, Serena Mora, Valentina Aristarco, Debora Macis, Fabio Bassi, Alberto Luini, Matteo Lazzeroni, Bernardo Bonanni & Michael N. Pollak. (2014) Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Research and Treatment 148:1, pages 81-90.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.